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Editorial
=========

Due to the ongoing research on a clinically relevant subject such as the cardiotoxic effects of oncologic drugs as exemplified by Finkelman et al. in the article "Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer" \[[@REF1]\], we wanted to point out some of the challenges faced when trying to stratify such cardiovascular risk. An extensive report of the incidences of cardiovascular adverse effects of oncologic drugs is presented, with the main purpose of highlighting not only the risk of developing heart failure but also the importance of the associated vascular adverse effects (i.e., hypertension, venous and arterial thrombosis) experienced by patients in the post-chemotherapy phase.

The most confusing aspect of the definition of cardiotoxicity is whether only clinical, clinical and subclinical, or only subclinical events should be considered \[[@REF2]\]. Another major clinical difficulty is related to the timing of detection of myocardial damage, since a measurement of left ventricular ejection fraction at some time point during or after therapy is clearly insufficient \[[@REF3]\]. If a biomarker allowed us to better stratify patients, and to initiate cardioprotective therapy in those patients at the earliest sign of toxicity, new efficient interventions could substantially improve outcomes \[[@REF3]\].

Endothelial biomarkers are gaining interest; it is known that bevacizumab decreases endothelial nitric oxide synthase activity, which may stimulate plasminogen activator inhibitor-1 expression, leading to an increased risk of hypertension \[[@REF4]\]. Finkelman et al. reported that plasma levels of endothelium biomarkers such as arginine, citrulline, and dimethylarginine were altered during the early phase of treatment with anthracycline-based chemotherapy \[[@REF1]\]. As mentioned by Lenihan \[[@REF3]\], if the predominant mechanism of early cardiotoxicity related to anthracycline administration were actually vascular in nature, it would substantially change potential prevention and treatment strategies. The severity of these adverse effects may not present in an early catastrophic manner as it would likely happen secondary to direct cardiotoxicity (e.g., systolic dysfunction), but they could highly impact the long-term prognosis.

Herrmann J et al. proposed a Cardiotoxicity Risk Score (CRS) that included a medication-related risk depending on incidence rates of cardiotoxicity \[[@REF5]\]. The cut-off values for these categories were \>15% (high), 15% -- 5% (moderate), \<5% (mild) and \<1% (rare), which we used to categorize the risk in this brief communication. A thorough review of the literature in Dailymed (US National Library of Medicine), UpToDate®️, US Food and Drug Administration (FDA) approved drug online registry and Pubmed (Medical Subject Headings terms: \"Adverse effects\", \"Drug-related Side Effects and Adverse Reactions\") was conducted, looking for incidences of cardiotoxicity of oncologic drugs. It is pertinent to mention that the heterogeneity of the information made this analysis more challenging. For e.g., the time point when cardiotoxicity becomes clinically evident varies substantially; this is the reason why different follow-up periods have been used. Furthermore, the different types of populations (e.g., naïve vs. relapse), different regimens, patient's Eastern Cooperative Oncology Group (ECOG) performance status, and disease stage and grade, add complexity to the conclusions achieved (Table [1](#TAB1){ref-type="table"}). Literature is vast regarding the data here cited. Due to the nature of this brief editorial, only the most relevant references have been listed; however, the authors would be more than pleased to e-mail the full list of sources to the readers who do require so.

###### Reported incidences (%) of cardiovascular adverse effects of oncologic drugs

  ----------------------------------------------------------------------------------------------------------------------------------------------------- ----------- ---------------- -------- ------ ------------------ ------ ----------------------
  Drug                                                                                                                                                   HF          Prolonged QTc    A-fib    MI    HTN (all grades)    VTE    Arterial thrombosis
  Anthracyclines (Doxorubicin)                                                                                                                                      14.0                                                        
  Doxorubicin 400 mg/m2                                                                                                                                 5.0                                                                     
  Doxorubicin 550 mg/m2                                                                                                                                 26.0                                                                    
  Doxorubicin 700 mg/m2                                                                                                                                 48.0                                                                    
  Trastuzumab                                                                                                                                           20.1^(a)^                                    4.0                        
  Ifosfamide                                                                                                                                                                         1.0                                        
  Ifosfamide \<10 g/m2                                                                                                                                  0.5                                                                     
  Ifosfamide 12.5--16 g/m2                                                                                                                              17.0                                                                    
  Cyclophosphamide                                                                                                                                      28.0                                                                    
  Clofarabine                                                                                                                                           27.0                                         13.0                       
  Carfilzomib                                                                                                                                           25.0                                         42.0               2.0     
  Sunitinib                                                                                                                                             18.0        4.0                              27.0               3.0    1.4
  Pazopanib                                                                                                                                             11.0        2.0                       2.0    40.0               5.0    0.3
  Sorafenib                                                                                                                                             8.0                                   3.0    15.3                      1.7
  Trametinib                                                                                                                                            11.0                                         15.0                       
  Dabrafenib                                                                                                                                            9.0         2.0                              4.0                        
  Docetaxel                                                                                                                                             13.0                         1.0      1.7                               
  Pertuzumab                                                                                                                                            7.0                                                                     
  Daunorubicin                                                                                                                                          10.1                                                                    
  Bevacizumab                                                                                                                                           4.0^(b)^                              1.5    23.6               33.0   6.0
  Ramucirumab                                                                                                                                                                                        16.0                      2.0
  Imatinib mesylate                                                                                                                                     2.7                          1.0      0.1    4.0                        
  Dasatinib                                                                                                                                             4.0         3.0              1.0      4.0    1.0                        
  Lapatinib                                                                                                                                             1.5         16.0                                                        
  Nilotinib                                                                                                                                             1.0         10.0                      9.0    11.0                      15.0
  Bortezomib                                                                                                                                            5.0                          1.0                                        
  Cisplatin                                                                                                                                                                                                             8.5    2.0
  Osimertinib                                                                                                                                           1.9         2.9                                                         
  Ado-trastuzumab emtansine                                                                                                                             2.0                                          5.0                        
  Lenvatinib                                                                                                                                            2.0                                          73.0                      5.0
  Cabozantinib                                                                                                                                                                                       61.0               9.0    2.0
  Ponatinib                                                                                                                                             9.0                          7.0      35.0   74.0               6.0     
  Lenalidomide                                                                                                                                          1.0                                   1.7    8.0                10.0    
  Arsenic trioxide                                                                                                                                                  40.0                             10.0                       
  Rituximab                                                                                                                                                                                          12.0                       
  Temsirolimus                                                                                                                                          1.0                                          7.0                2.0     
  Everolimus                                                                                                                                            1.0                          1.0             30.0                       
  Sirolimus                                                                                                                                                                                          49.0                       
  Ibrutinib                                                                                                                                                                          9.0             17.0                       
  Alemtuzumab                                                                                                                                                                                        14.0                       
  Gefitinib                                                                                                                                                                                          9.0                       1.0
  Ibritumumab tiuxetan                                                                                                                                                                               7.0                        
  Daratumumab                                                                                                                                                                                        10.0                       
  Pembrolizumab                                                                                                                                                                                      7.0                        
  Ofatumumab                                                                                                                                                                                         5.0                        
  Paclitaxel                                                                                                                                            1.0                                   5.0                       1.0     
  Thalidomide                                                                                                                                                                                 3.0                       22.0    
  Erlotinib                                                                                                                                                                                   2.3                       11.0    
  Vorinostat                                                                                                                                                        6.0                                                 8.0     
  Atezolizumab                                                                                                                                                                                                          10.0    
  Panitumumab                                                                                                                                                                                                           3.0     
  Nivolumab                                                                                                                                                                                                             3.0     
  Cetuximab                                                                                                                                                                                   2.0                               
  Cytarabine \[Liposomal\]                                                                                                                                                                           6.0                        
  5-fluorouracil                                                                                                                                                                                                        6.0     
  Capecitabine                                                                                                                                                                       5.0                                8.0     
  The incidences are the highest reported in literature.                                                                                                                                                                       
  \(a\) When used in combination with anthracyclines and cyclophosphamide. (b) In patients receiving concurrent anthracyclines.                                                                                                
  A-fib: atrial fibrillation; HF: heart failure; HTN: hypertension; MI: myocardial ischemia; QTc: corrected QT interval; VTE: venous thromboembolism.                                                                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------- ----------- ---------------- -------- ------ ------------------ ------ ----------------------

As depicted in Figure [1](#FIG1){ref-type="fig"}, some drugs primarily affect cardiac function (i.e., anthracyclines and trastuzumab), vascular function (e.g., 5-fluorouracil and capecitabine), or both (e.g., bevacizumab and sunitinib); information concordant with current accepted and potential mechanisms \[[@REF5]\]. Tyrosine kinase inhibitors (TKIs) present a risk of vascular damage associated with moderate (i.e., sunitinib, pazopanib, sorafenib, trametinig) or mild (i.e., levantinib, carbozantinib, ponatinib) risk of myocardium injury. Likewise, monoclonal antibodies (Ab) such as bevacizumab (VEGF Ab) and ado-trastuzumab (HER2 Ab) have a mixed effect, whereas rituximab (CD20 Ab), alemtuzumab (CD52 Ab) and daratumumab (CD38 Ab) report almost exclusive vascular adverse effects. Interestingly, some drugs, such as anthracyclines \[[@REF1]\], have been recently associated with vascular damage, which reveals the importance of research in identifying new biomarkers that could be used to improve cardiotoxicity risk scores.
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Through this manuscript, we would like to reinforce the idea that when addressing cardiotoxicity, not only should the myocardium be considered in our evaluation but also the endothelium. The latter could play an important role in how our patients face the early and late post-chemotherapy phase, thus helping to stratify patients\' risks and optimize their management.
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